CellCentric: Series DDevelops inobrodib, a first-in-class oral p300/CBP inhibitor for relapsed or refractory multiple myelomaOct 4, 2026RoundOSCellCentricCompany profile and funding historySourcesbusinesswire.comMore in BiotechAusperBio · Series CProFound Therapeutics · StrategicTransfyr · SeedBiotechUnited KingdomHealthtechEuropeSeries C+